权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Pre-Cessation Effects of Bupropion on Smoking

安非他酮对吸烟的戒烟前影响

基本信息

批准号：
7140127
负责人：
LARRY W HAWK
金额：
$ 12.81万
依托单位：
STATE UNIVERSITY OF NEW YORK AT BUFFALO
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-08-15 至 2008-06-30
项目状态：
已结题

项目摘要

DESCRIPTION (provided by applicant): In clinical trials bupropion has been shown to double long-term smoking cessation rates. Nevertheless, most smokers using bupropion relapse back to smoking within the first few weeks of cessation. Bupropion has been hypothesized to help smokers to quit in part by reducing the reinforcing effects of smoking during the typical 1-week pre-quitting treatment phase. Learning theory and previous basic human and animal research support the hypothesis that a longer duration of bupropion treatment prior to the target quit date (TQD) will yield greater decreases in smoking satisfaction and the number of cigarettes smoked per day before quitting, and higher rates of continuous cessation after quitting. The proposed research is the first study of which we are aware to systematically vary the pre-quitting duration of bupropion treatment in smokers to test these predictions. A two group randomized experimental design will be used. One hundred male and female smokers who are motivated to quit smoking will be randomized to a brief run-in group (3 weeks of placebo, followed by the typical 1 week of pre-TQD bupropion) and an extended run-in group (4 weeks of pre-TQD bupropion). Both groups will receive 7 weeks of post-TQD bupropion, as well as group behavioral counseling for smoking cessation. During the pre-quitting treatment phase we predict that bupropion will reduce the number of cigarettes smoked daily and smoking satisfaction, relative to placebo. During a 3-month post-quitting phase, we predict that relapse will be lower in those who experience the greatest pre-quit reductions in smoking rate and satisfaction. We will conduct exploratory analyses of whether cessation is greater for subjects in the extended run-in group compared to the brief run-in group, and whether this effect is mediated by differences in the pre-quit effects of bupropion. This theory-based research may lead to enhanced treatment with bupropion and more broadly stimulate programmatic basic and clinical studies that improve cancer control through a better understanding of learning and behavioral processes implicated in pharmacotherapy for tobacco cessation.

描述（由申请人提供）：在临床试验中，安非他酮已被证明可以使长期戒烟率翻倍。然而，大多数使用安非他酮的吸烟者在戒烟后的最初几周内又重新吸烟。据推测，安非他酮可以部分通过在典型的 1 周戒烟前治疗阶段减少吸烟的强化作用来帮助吸烟者戒烟。学习理论和之前的人类和动物基础研究支持这样的假设：在目标戒烟日期 (TQD) 之前较长时间的安非他酮治疗会导致吸烟满意度和戒烟前每天吸烟数量的更大下降，以及戒烟后持续戒烟的更高比率。拟议的研究是我们所知的第一项系统地改变吸烟者戒烟前安非他酮治疗持续时间以测试这些预测的研究。将使用两组随机实验设计。 100 名有戒烟动机的男性和女性吸烟者将被随机分为短期磨合组（3 周安慰剂，然后是典型的 TQD 前安非他酮 1 周）和长期磨合组（TQD 前安非他酮 4 周）。两组患者在 TQD 后都将接受 7 周的安非他酮治疗，以及戒烟团体行为咨询。在戒烟前治疗阶段，我们预测相对于安慰剂，安非他酮将减少每天吸烟的数量和吸烟满意度。在戒烟后 3 个月的阶段，我们预测戒烟前吸烟率和满意度下降幅度最大的人的复吸率会较低。我们将进行探索性分析，以确定与短暂磨合组相比，长期磨合组的受试者戒烟是否更严重，以及这种效应是否是由安非他酮戒烟前效应的差异介导的。这项基于理论的研究可能会导致安非他酮治疗的加强，并更广泛地刺激计划性基础和临床研究，通过更好地了解戒烟药物治疗中涉及的学习和行为过程来改善癌症控制。